Development PipelineSEA-BCMA

an investigational sugar-engineered antibody directed to the B-cell maturation antigen

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

SGNBCMA-001: Relapsed/refractory multiple myeloma

  • Phase 1

  • Phase 2

  • Phase 3

Program Resources

High-level synopsis of BCMA and ongoing clinical trials

Detailed information about BCMA clinical trials